Ken Griffin Innoviva, Inc. Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$14.4 - $16.4 $184,320 - $209,919	12,800 Added 177.78%	20,000 $328,000
Q1 2024 May 15, 2024	BUY	$14.56 - $16.78 $55,328 - $63,764	3,800 Added 111.76%	7,200 $109,000
Q4 2023 Feb 14, 2024	SELL	$12.32 - $16.27 $183,568 - $242,423	-14,900 Reduced 81.42%	3,400 $54,000
Q3 2023 Nov 14, 2023	SELL	$12.37 - $13.89 $16,080 - $18,057	-1,300 Reduced 6.63%	18,300 $237,000
Q2 2023 Aug 14, 2023	BUY	$11.39 - $13.72 $154,904 - $186,592	13,600 Added 226.67%	19,600 $249,000
Q1 2023 May 15, 2023	SELL	$10.73 - $13.6 $1,073 - $1,360	-100 Reduced 1.64%	6,000 $67,000
Q4 2022 Feb 14, 2023	SELL	$11.8 - $13.78 $816,560 - $953,576	-69,200 Reduced 91.9%	6,100 $80,000
Q3 2022 Nov 14, 2022	SELL	$11.61 - $15.22 $147,447 - $193,294	-12,700 Reduced 14.43%	75,300 $874,000

222

79.7M

20K

5.4K

Ticker INVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,706,000
Market Cap $1.37B
Description
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.